This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n4http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/drugbank/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/national-drug-code-directory/
n21http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n20http://www.drugs.com/mtm/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/chemspider/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/chebi/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n30http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/kegg-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01138/identifier/pubchem-compound/
n28http://linked.opendata.cz/resource/atc/
n3http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01138
rdf:type
n5:Drug
n5:description
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. [PubChem]
n5:dosage
n7:271B4766-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
Approximately 4-6 hours
n5:indication
For the treatment of gout and gouty arthritis.
owl:sameAs
n18:DB01138 n21:DB01138
dcterms:title
Sulfinpyrazone
adms:identifier
n11:PA451550 n12:5342 n13:D00449 n14:0083-0041-30 n16:46504918 n19:9342 n22:C07317 n23:5149 n24:DB01138 n29:Sulfinpyrazone
n5:mechanismOfAction
Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. This is likely done through inhibition of the urate anion transporter (hURAT1) as well as the human organic anion transporter 4 (hOAT4). Sulfinpyrazone is not intended for the treatment of acute attacks because it lacks therapeutically useful analgesic and anti-inflammatory effects. Sulfinpyrazone and its sulfide metabolite possess COX inhibitory effects. Sulfinpyrazone has also been shown to be a UDP-glucuronsyltransferase inhibitor and a very potent CYP2C9 inhibitor. Sulfinpyrazone is also known to be a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor as well as an inhibitor of several multridrug resistance proteins (MRPs).
n5:packager
n15:271B4760-363D-11E5-9242-09173F13E4C5 n15:271B4761-363D-11E5-9242-09173F13E4C5 n15:271B4762-363D-11E5-9242-09173F13E4C5 n15:271B4763-363D-11E5-9242-09173F13E4C5 n15:271B4764-363D-11E5-9242-09173F13E4C5
n5:synonym
1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione Anturane (tn) 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine Sulfoxyphenylpyrazolidine Sulfinpyrazone
n5:toxicity
Symptoms of overdose include nausea, vomiting, diarrhea, epigastric pain, ataxia, labored respiration, convulsions, coma. Possible symptoms, seen after overdosage with other pyrazolone derivatives: anemia, jaundice, and ulceration.
n3:hasAHFSCode
n4:40-40-00
n5:proteinBinding
98-99%
n25:hasConcept
n26:M0020776
foaf:page
n9:sulfinpyrazone.htm n20:sulfinpyrazone.html
n5:IUPAC-Name
n6:271B476B-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4771-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4770-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B476D-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B476E-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B476F-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4781-363D-11E5-9242-09173F13E4C5 n6:271B4769-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4767-363D-11E5-9242-09173F13E4C5 n6:271B4783-363D-11E5-9242-09173F13E4C5 n6:271B476A-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4768-363D-11E5-9242-09173F13E4C5
n5:pKa
n6:271B4784-363D-11E5-9242-09173F13E4C5
n3:hasATCCode
n28:M04AB02
n5:H-Bond-Acceptor-Count
n6:271B4777-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4778-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4772-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4773-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4775-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4774-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4776-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
57-96-5
n5:category
n5:containedIn
n30:271B4765-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B477D-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B477F-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4780-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B4782-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B477C-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B477B-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B477E-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B476C-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4779-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B477A-363D-11E5-9242-09173F13E4C5